More than 50% of the infected patients develop a chronic, long-term disease, characterized by a debilitating arthralgia that can persist for weeks to months.

Death from MAYV is rare.

The virus is endemic to the tropical forests of the Amazon and was repeatedly detected in humans and mosquitoes in Latin America and the Caribbean. Despite being rarely fatal, MAYV infections have high socioeconomic impact due to the chronic painful incapacitating phase of the disease. There are no approved vaccines or antivirals available at the moment for the prevention or treatment of MAYV infection.